Expression of MUC1, MUC2, MUC5AC, and MUC6 in Atypical Adenomatous Hyperplasia, Bronchioloalveolar Carcinoma, Adenocarcinoma With Mixed Subtypes, and Mucinous Bronchioloalveolar Carcinoma of the Lung

American Journal of Clinical Pathology

Volumn 121, Issue 5, 2004, Pages 644-653

  Awaya, Hirokazu ^a   Takeshima, Yukio ^a   Yamasaki, Masahiro ^a,b   Inai, Kouki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Mitsugi Public General Hospital   (Japan)

Author keywords

Adenocarcinoma; Atypical adenomatous hyperplasia; Bronchioloalveolar carcinoma; Lung; MUC

Indexed keywords

KI 67 ANTIGEN; MUCIN 1; MUCIN 2; MUCIN 5AC; MUCIN 6; PROTEIN P53;

ADULT; AGED; ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOGENESIS; LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 2042497140     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/U4WGE9EBFJN6CM8R     Document Type: Article

References (32)

1. Wynder EL, Hoffmann D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res. 1994;54:5284-5295.
2. Yang ZG, Sone S, Takashima S, et al. High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT. AJR Am J Roentgenol. 2001;176:1399-1407.
3. Travis WD, Colby B, Corrin B, et al. Histological Typing of Lung and Pleural Tumours. 3rd ed. Berlin, Germany: Springer; 1999. World Health Organization International Histological Classification of Tumours.
4. Koga T, Hashimoto S, Sugio K, et al. Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia. Am J Clin Radiol. 2002;117:464-470.
5. Niho S, Yokose T, Suzuki K, et al. Monoclonality of atypical adenomatous hyperplasia of the lung. Am J Pathol. 1999;154:249-254.
6. Mori M, Rao SK, Popper HH, et al. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol. 2001;14:72-84.
7. Yamasaki M, Takeshima Y, Fujii S, et al. Correlation between genetic alteration and histopathological subtypes in bronchiolo-alveolar carcinoma and atypical adenomatous hyperplasia of the lung. Pathol Int. 2000;50:778-785.
8. Slebos RJ, Baas IO, Clement MJ, et al. p53 alterations in atypical alveolar hyperplasia of the human lung. Hum Pathol. 1998;29:801-808.
9. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996;56:2224-2228.
10. Hayashi H, Ito T, Yazawa T, et al. Reduced expression of p27/kipl is associated with the development of pulmonary adenocarcinoma. J Pathol. 2000;192:26-31.
11. Seiki N, Takasu T, Mandai K, et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res. 2002;8:3046-3053.
12. Baldus SE, Monig SP, Hanisch FG, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis (a) and sialyl-Lewis (x) antigens in colorectal adenocarcinoma. Histopathology. 2002;40:440-449.
13. Jang KT, Chae SW, Sohn LH, et al. Coexpression of MUC1 with p53 or MUC2 correlates with lymph node metastasis in colorectal carcinomas. J Korean Med Sci. 2002;17:29-33.
14. Rahn JJ, Dabbagh L, Pasdar M, et al. The importance of MUC1 cellular localization in patients with breast carcinoma. Cancer. 2001;91:1973-1982.
15. Jarrard JA, Linnoila RI, Lee H, et al. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res. 1998;58:5582-5589.
16. Makiguchi Y, Hinoda Y, Imai K. Effect of MUC1 mucin and anti-adhesion molecule on tumor cell growth. Jpn J Cancer Res. 1996;87:505-511.
17. Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) over-expression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995;129:255-265.
18. Kondo K, Kohno N, Yokoyama A, et al. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 1998;58:2014-2019.
19. van de Wiel-van Kemenade E, Lightenberg MJL, de Boer AJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol. 1993;151:767-776.
20. Sasaki M, Yamamoto T, Nakanuma Y, et al. Expression of MUC2, MUC5AC and MUC6 apomucins in carcinoma, dysplasia and non-dysplastic epithelia of the gall bladder. Pathol Int. 1999;49:38-44.
21. Kim GE, Bae HI, Park HU, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002;123:1052-1060.
22. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol. 1996;49:560-564.
23. Guddo F, Giatromanolaki A, Patriarca C, et al. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res. 1998;18:1915-1920.
24. Guddo F, Giatromanolaki A, Koukourakis MI, et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol. 1998;51:667-671.
25. Lopez-Ferrer A, Curull V, Barranco C, et al. Mucins as differentiation markers in bronchial epithelium: squamous cell carcinoma and adenocarcinoma display similar expression patterns. Am J Respir Cell Mol Biol. 2001;24:22-29.
26. Hanski C, Riede E, Gratchev A, et al. MUC2 gene suppression in human colorectal carcinomas and their metastasis: in vitro evidence of the modulatory role of DNA methylation. Lab Invest. 1997;77:685-695.
27. Perrais M, Pigny P, Copin MC, et al. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/ extracellular signal-regulated kinase cascade and Sp1. J Biol Chem. 2002;30:32258-32267.
28. Van Seuningen I, Pigny P, Perrais M, et al. Transcriptional regulation of the 11p15 mucin genes: towards new biological tools in human therapy, in inflammatory disease and cancer? Front Biosci. 2001;6:1216-1234.
29. Ookawa K, Kudo T, Aizawa S, et al. Transcriptional activation of the MUC2 gene by p53. J Biol Chem. 2002;50:48270-48275.
30. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol. 1996;179:254-259.
31. Barsky SH, Cameron R, Osann KE, et al. Rising incidence of bronchioloalveolar carcinoma and its unique clinicopathologic features. Cancer. 1994;15:1163-1170.
32. Jepson S, Komatsu M, Haq B, et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinase B/Akt pathways. Oncogene. 2002;21:7524-7532.